Biguanide Market to Reach $8.1 Billion by 2035

Biguanide market was valued at $5.8 billion in 2025 and is projected to reach $8.1 billion by 2035, growing at a CAGR of 3.5% during the forecast period (2026–2035). The increasing global burden of diabetes, particularly type 2 diabetes, is significantly strengthening demand for biguanide-based therapies. Biguanides, especially metformin, remain the first-line pharmacological treatment due to their proven efficacy, safety profile, and cost-effectiveness. Rising awareness regarding early diagnosis and long-term glycemic control is further driving prescription volumes across both developed and emerging healthcare markets.

Browse the full report description of “Biguanide Market Size, Share & Trends Analysis Report, By Product Type (Metformin IR, Metformin ER, Phenformin, Buformin, Polyhexamethylene Biguanide), By Drug Form (Oral Tablets, Oral Solutions, Topical Formulations), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/biguanide-market

The market continues to be dominated by metformin-based formulations, with both immediate-release (IR) and extended-release (ER) variants supporting widespread adoption. Oral tablets remain the primary drug form due to convenience and patient compliance, while topical formulations such as Polyhexamethylene biguanide (PHMB) are witnessing gradual adoption in antimicrobial and wound care applications. Expanding access to essential medicines and increasing healthcare expenditure in developing economies are further supporting market growth.

Rising Diabetes Prevalence Driving Biguanide Demand

According to the World Health Organization (WHO), the number of people living with diabetes globally rose to approximately 830 million, with type 2 diabetes accounting for over 90% of cases. In 2023, the International Diabetes Federation (IDF) estimated that global diabetes prevalence reached 537 million adults and is expected to rise to 643 million by 2030. This increasing disease burden is placing sustained pressure on healthcare systems to adopt cost-effective and scalable treatment solutions, directly supporting the demand for biguanide drugs such as metformin.

In addition, government-led initiatives aimed at improving diabetes care and accessibility to essential medicines are further strengthening market growth. For instance, under India’s National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), the government expanded screening and treatment coverage between 2023 and 2025, significantly increasing access to antidiabetic medications at primary healthcare levels. Such initiatives are accelerating early diagnosis and treatment uptake, reinforcing demand for biguanide-based therapies across large patient populations.

Despite the emergence of newer antidiabetic drug classes, biguanides continue to maintain a strong position due to their affordability and inclusion in essential medicines lists across multiple countries. The increasing integration of combination therapies and fixed-dose formulations is also supporting long-term utilization of biguanides in diabetes management protocols.

Strategic Developments Strengthening Market Position

The key players in the biguanide market include Merck KGaA, Sanofi, Bristol-Myers Squibb, Teva Pharmaceutical Industries, and Sun Pharmaceutical Industries, among others. These companies are focusing on expanding their generic portfolios, enhancing production capabilities, and strengthening distribution networks to meet the growing global demand for antidiabetic medications.

• In March 2026, Sun Pharmaceutical Industries Limited strengthened its presence in the Biguanide (anti-diabetic) market through the launch of semaglutide-based therapies, Noveltreat and Sematrinity, in India. These GLP-1 treatments target type 2 diabetes and obesity management, complementing traditional biguanide therapies like metformin by offering more advanced and effective treatment options.
• In August 2025, Merck KGaA strengthened its strategic position in the Biguanide market by divesting its non-core Surface Solutions business to Global New Material International Holdings Ltd. for €665 million. This move allows Merck to sharpen its focus on core, technology-driven healthcare and life sciences segments, including pharmaceuticals.

Market Coverage

• The market number available for – 2025–2035
• Base year – 2025
• Forecast period – 2026–2035
• Segment Covered –
• By Product Type
• By Drug Form
• Competitive Landscape – Merck KGaA, Sanofi, Bristol-Myers Squibb, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, among others.

Key Questions Addressed by the Report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Biguanide Market Segment

By Product Type

• Metformin IR
• Metformin ER
• Phenformin
• Buformin
• Polyhexamethylene Biguanide (PHMB)

By Drug Form

• Oral Tablets
• Oral Solutions
• Topical Formulations (PHMB-based)

Global Biguanide Market Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/biguanide-market